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ABSTRACT
ObjectivesTodeterminetheaccuracyandacceptabilityto
patients of non-endoscopic screening for Barrett’s
oesophagus, using an ingestible oesophageal sampling
device (Cytosponge) coupled with immunocytochemisty
for trefoil factor 3.
Design Prospective cohort study.
Setting 12 UK general practices, with gastroscopies
carried out in one hospital endoscopy unit.
Participants 504 of 2696 eligible patients (18.7%) aged
50 to 70 years with a previous prescription for an acid
suppressant (H2 receptor antagonist or proton pump
inhibitor) for more than three months in the past five
years.
Main outcome measures Sensitivity and specificity
estimates for detecting Barrett’s oesophagus compared
withgastroscopyastheidealmethod,andpatientanxiety
(short form Spielberger state trait anxiety inventory,
impactofeventsscale)andacceptability(visualanalogue
scale) of the test.
Results 501 of 504 (99%) participants (median age 62,
male to female ratio 1:1.2) successfully swallowed the
Cytosponge.Noseriousadverseeventsoccurred.Intotal,
3.0% (15/501) had an endoscopic diagnosis of Barrett’s
oesophagus (≥1 cm circumferential length, median
circumferential and maximal length of 2 cm and 5 cm,
respectively) with intestinal metaplasia. Compared with
gastroscopy the sensitivity and specificity of the test was
73.3% (95% confidence interval 44.9% to 92.2%) and
93.8% (91.3%to 95.8%)for 1 cm or morecircumferential
lengthand90.0%(55.5%to99.7%)and93.5%(90.9%to
95.5%) for clinically relevant segments of 2 cm or more.
Most participants (355/496, 82%, 95% confidence
interval 78.9% to 85.1%) reported low levels of anxiety
before the test, and scores remained within normal limits
at follow-up. Less than 4.5% (2.8% to 6.1%) of
participants reported psychological distress a week after
the procedure.
Conclusions The performance of the Cytosponge test was
promising and the procedure was well tolerated. These
data bring screening for Barrett’s oesophagus into the
realm of possibility. Further evaluation is recommended.
INTRODUCTION
The incidence of oesophageal adenocarcinoma, for
which Barrett’s oesophagus is the main risk factor,
has increased sixfold in the Western world since the
1990s.
1 Meta-analyses suggest that the risk for conver-
sion from Barrett’s oesophagus to adenocarcinoma is
0.5% per year and this conversion is thought to occur
up to 15 years after diagnosis.
2 This cancer has in
excess of 80% mortality at five years unless detected
early (also called intraepithelial neoplasia).
3 Oesopha-
gectomy has formed the basis for curative treatment
even in patients with surveillance detected asympto-
matic disease. However, because of the 5% mortality
and significant morbidity associated with this highly
invasive surgery, little enthusiasm has been shown for
diagnosing Barrett’s oesophagus at a population level.
ThetreatmentsforintraepithelialneoplasiainBarrett’s
oesophagus have recently undergone a paradigm shift
with the rapid development of outpatient endoscopic
technologies, such as mucosal resection and radio-
frequency ablation.
4-6 The feasibility for endoscopic
treatment now means that more systematic screening
forBarrett’soesophagusmeritsfurtherconsideration.
7
The ideal method for diagnosing Barrett’s oesopha-
gus is white light gastroscopy and biopsy, despite lim-
itations such as the invasiveness of the procedure, the
need for great expertise, the high cost, and the subjec-
tive nature of the diagnosis. However, limited endo-
scopy and fiscal resources may restrict the use of this
procedure in large, population based screening pro-
grammes, and many people may be reluctant to
undergo hospital based gastroscopy because of its
inconvenience and discomfort.
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Donaldson, in his 2008 report, a need exists for a safe,
minimally invasive, cheap, and easily administered
method aimed at the primary care setting to diagnose
Barrett’s oesophagus.
710 We have shown that non-
endoscopic screening is feasible and safe using a new
device called the capsule sponge, or Cytosponge.
11 To
distinguish Barrett’s cells from a mixed cell popula-
tion, including gastric cardia and squamous epithe-
lium, we have coupled the device with an
immunohistochemical biomarker, trefoil factor 3.
11
We determined the accuracy and acceptability of
using the Cytosponge combined with trefoil factor 3
as a non-endoscopic procedure for the detection of
Barrett’s oesophagus in primary care.
METHODS
This prospective cohort study was undertaken in
12 general practices in the United Kingdom. The out-
come measures were sensitivity and specificity esti-
mates for detecting Barrett’s oesophagus compared
withgastroscopyastheidealmethodtoinformafuture
study, and patient anxiety and acceptability of under-
going the test.
Setting and recruitment
We identified eligible patients by searching the pre-
scribing database of the 12 primary care practices for
adultsaged 50to70witha previousprescriptionforan
acid suppressant (H2 receptor antagonist or proton
pump inhibitor) for more than three months in the
past fiveyears.Exclusion criteriawere a previousdiag-
nosis of Barrett’s oesophagus, gastroscopy within the
past year, dysphagia, known portal hypertension,
drug or pathophysiological abnormality of coagula-
tion, important physical or psychological comorbidity
precluding gastroscopy, or the inability to provide
informed consent. The number of general practices
was based on previous studies based in primary care
reporting that 16.3% of patients with reflux symptoms
agreedtoendoscopy.
12Thegeneralpracticessenteligi-
ble participants an invitation letter. Responders who
agreed to take part were sent an appointment for the
Cytosponge test at the general practice. Recruitment
continueduntilmorethan500peoplehadparticipated.
Study procedures
Appointment in general practice and questionnaire follow-up
After written informed consent had been obtained the
participants completed a sociodemographic and clini-
calquestionnaireandanassessmentofsymptoms(gas-
tro-oesophageal reflux disease impact score
13).
The research nurse or research fellow (gastro-
enterologist in specialist training) administered the
Cytosponge, an ingestible gelatine capsule containing
a compressed mesh attached to a string. The Cytos-
ponge was approved by the UK Medical Health Reg-
ulatory Agency in 2008 (fig 1). Briefly, the capsule and
bunchedupstringareswallowedwithwater.Thestring
is held without any tension to allow the capsule to
move into the stomach. The patient holds onto the
string for five minutes after ingestion to allow the cap-
suletodissolveintheproximalstomach,whereasphe-
ricalmeshof3cmdiameterisreleased.Thebackofthe
throat is then sprayed with 1% lidocaine (lignocaine)
and the expanded mesh withdrawn by pulling on the
string with the patient’s head in an extended position.
AfterretrievalthestringiscutandtheCytospongecon-
tainingthecytologicalspecimenplacedinpreservative
fluid (gift from Surepath; BD Diagnostics, Durham,
NC, USA) and kept at room temperature until trans-
portation to the laboratory. The whole process of
administering the Cytosponge, including instructing
the patient, takes less than 10 minutes.
Within 30 minutes of the procedure the participants
completed a questionnaire including the short form
Spielberger state trait anxiety inventory,
14 the impact
ofeventsscale,
15andavisualanaloguescaletomeasure
acceptability.
16 The short form Spielberger state trait
anxiety inventory has been extensively used in studies
of disease screening. We prorated the scores as per
developers’guidelines,withascoreof40ormorecon-
sidered to represent clinically significant anxiety.
17 To
measure the effect of the Cytosponge on anxiety and
distress we used the impact of events scale. The scale
yields two scores assessing intrusive and avoidance
thoughts.Finalscoresrangebetween0and35forintru-
sion and 0 and 40 for avoidance (total score between 0
and 75), with values of more than 19 for each subscore
(38 for total score) representing high test induced dis-
tress and values below 8.5 for each subscore (17 for
total score) representing low distress.
15 We calculated
scores for participants who completed a minimum of
75% of questions on each subscore. The visual analo-
gue scale assessed acceptability of the procedure,
where 0 represented the “worst experience” and 10
the ”best experience.” Similar questionnaires were
posted to all participants seven and 90 days later.
Non-responders were sent one postal reminder and if
that failed one telephone reminder.
Laboratory processing of samples
To provide the patient with a prompt result we stored
the Cytosponge samples at room temperature and
Fig 1 | Cytosponge in gelatine capsule (right) and expanded
(left)
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storedintherefrigeratorat4°Cbeforeprocessingwith-
out affecting the assay result. Samples were processed
toparaffinblocks.Immunostainingwascarriedoutfor
trefoil factor 3, which we identified to be a diagnostic
markerofBarrett’soesophagusfromasystematicgene
expression profiling experiment.
11 Two independent
researchers, one with expertise in pathology (SK) and
a gastrointestinal cytopathologist (MO’D), reported
the findings. Sections stained for trefoil factor 3 were
scoredinabinaryfashionaseitherpositiveornegative.
Any glandular cells with trefoil factor 3 staining were
considered as positive and to make the result as robust
and objective as possible we used no intensity cut offs.
The κ statistic between the two scorers was 0.74, indi-
cating substantial agreement.
Gastroscopy: the ideal method
We invited those participants who had swallowed the
Cytosponge to attend for a gastroscopy within three
weeksofthescreeningtest.Thegastroscopieswerecar-
ried out at a single specialist unit by one of three endo-
scopists,whoadheredtoastrictdiagnosticprotocol.In
viewofthe lackofa universallyaccepteddefinitionfor
Barrett’soesophagus,
1we optedfor criteria thatwould
avoid mistaken identification of a hiatus hernia and
that were in line with the Prague classification guide-
lines. These guidelines recommend the use of the
length of Barrett’s oesophagus from the gastro-oeso-
phageal junction covering the circumference of the
oesophagus(circumferentiallengthorC)andthemax-
imal length of Barrett’s oesophagus from the gastro-
oesophageal junction (maximal length or M) for a
robust diagnosis.
18 Hence a patient with 1 cm of cir-
cumferential Barrett’s oesophagus with 2 cm of Bar-
rett’s tissue extending above the circumferential
segment above with a total length of 3 cm is described
as having Barrett’s oesophagus C1M3. Barrett’s oeso-
phaguswasdefinedasendoscopicallyvisiblecolumnar
lined epithelium arisingat least 1 cm circumferentially
(C1)abovethegastro-oesophagealjunctionwithintest-
inal metaplasia. Trefoil factor 3 was ascertained as a
marker of intestinal metaplasia,
11 as it is the subtype
most strongly associated with a risk of malignancy.
19
Weanalysedthedataaccordingtotwocircumferential
length cut offs, 1 cm or more and 2 cm or more, since
the reliability of endoscopic diagnosis increases signif-
icantly with length.
18 We defined the gastro-oesopha-
geal junction by using the upper end of the gastric
longitudinal mucosal folds as landmarks.
20 To check
for confounding by intestinal metaplasia of the sto-
mach we assessed samples from the cardia and 2 cm
above the squamocolumnar junction in all partici-
pants. If Barrett’s oesophagus was present, we col-
lected additional four biopsies every 2 cm according
to surveillance guidelines, which were reviewed by a
gastrointestinal pathologist (MO’D) with extensive
experience in Barrett’s oesophagus.
19 Endoscopists
and histopathologists were blinded to the result of the
Cytosponge.
Statistical analysis
Based on assumed sensitivity and specificity of 75%
and 85% and a prevalence of Barrett’s oesophagus of
3%, powercalculations indicated that to obtain an esti-
matewitha95%confidenceintervalplusorminus15%
we required 500 participants. Statistics for continuous
variables were expressed as medians and interquartile
ranges.WeusedaMann-Whitneytesttocomparecon-
tinuous or ordinal variables between groups and a χ
2
test to compare categorical variables. Accuracy of the
test was reported using Pearson Clopper exact 95%
confidence intervals. All reported P values were two
sided. Statistical analyses were carried out using
Prism V5.01.
RESULTS
Twelve general practices covering a population of
100668 were recruited over 20 months from May
2008 to December 2009 (fig 2). In total, 2696 patients
identifiedfromthepracticeprescribingdatabaseswere
eligible and invited to take part in the study; 504
(18.7%) agreed. The Cytosponge was successfully
swallowedby501(99%;threewereunabletoswallow).
TwoCytospongesfailedtofullyexpandandthecorre-
sponding samples had a low cell yield. All
501 participants were included in the analysis and
those who did not attend for gastroscopy (n=32) were
considered not to have Barrett’s oesophagus. No
General practices (total list size 100 668) (n=12)
Eligible patients (n=2696)
Not interested (n=2069):
  No reply (n=1666)
  Declined (n=403)
Agreed to take part (n=627, 23.2% of eligible patients)
Consented to study (n=504, 18.7% of eligible patients)
Swallowed Cytosponge successfully (n=501, 18.6% of
eligible patients, 99.0% of patients who attended clinic)
Completed study (n=467, 17.3% of
eligible patients, 92.3% of patients who attended clinic)
Patients did not attend Cytosponge appointment (n=123):
  Could not be contacted (n=6)
  Withdrew (n=79)
  Missed appointment (n=11)
  Met exclusion criteria (n=25)
  Did not provide consent (n=2)
Did not complete study (n=34):
  Incomplete expansion of Cytosponge (n=2)
  Declined gastroscopy (n=32)
Response rates for questionnaires
  Day 0: 498/501 (99%)
  Day 7: 465/501 (93%)
  Day 90: 419/501 (84%)
Unable to swallow Cytosponge (n=3)
Fig 2 | Flow of patients through trial
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ing the Cytosponge, in particular no bleeding or
aspiration.Nofailurestookplaceinthesampleproces-
sing or staining for trefoil factor 3.
Personal and clinical characteristics of participants
Table 1showsthepersonaland clinicalcharacteristics
of the study population. The numbers of men and
women were almost equal (male to female ratio 1:1.2)
with a median age of 62 years (interquartile range
56-66 years) in both sexes. The male to female ratio
(1:1.1) and median age (63 years, 58-67) of the non-
responders did not differ significantly from that of the
responders.The median waist to hip ratio for men was
0.96 (interquartile range 0.92-1.00), which falls within
the range considered to be a medium health risk, and
for women 0.86 (0.82-0.91), which is associated with a
highhealthrisk.
21Themedianbodymassindexof29.4
(26.2-32.9) indicated that most participants were over-
weight, with more than 45% in the obese range.
22
Overall, participants consumed less alcohol than the
national average,
23 but the proportion of smokers
(past and present) was 10% higher for each sex than
the national UK averages.
24 Only 68% of participants
(344/501) were currently taking prescribed acid sup-
pressants,butallmettheinclusioncriteriaofsuchther-
apy at some time in the past five years. Overall, 73%
(367/501) of participants reported uncontrolled to
very poorly controlled reflux symptoms according to
theimpactscoresforgastro-oesophagealrefluxdisease
(table 1).
13
Accuracy of the test
Based on standard gastroscopy the prevalence of Bar-
rett’s oesophagus was 3.0% (15/501) for segments of
circumferential length 1 cm or more and 2.2% (10/
501) for segments of 2 cm or more, with a median
length of C4M5 (interquartile range C1M2-C9M9)
(table 2).
Table 3showsthecharacteristicsofthepatientswith
a diagnosis of Barrett’s oesophagus categorised
according to the circumferential length of segment
(≥1c mo r≥2 cm) compared with those without Bar-
rett’s oesophagus. No statistical differences were
observed between the patients with Barrett’s oesopha-
gus (≥1 cm) and those without. If a cut off of 2 cm or
more was used, there was a higher prevalence of
tobaccosmokinginpatientswithBarrett’soesophagus
(P=0.03). The small sample size, however, precludes
definitive conclusions.
Figure 3 shows haematoxylin and eosin and trefoil
factor 3 staining of the Cytosponge specimen from a
representative segment of tissue from a patient with
Barrett’s oesophagus. For a cut off of 1 cm or more,
11 of 15 segments were detected with the Cytosponge,
giving a sensitivity of 73.3% (95% confidence interval
44.9% to 92.2%). For a cut off of 2 cm or more nine of
10 segments were detected, giving a sensitivity of
90.0% (55.5% to 99.7%). The specificity was 93.8%
(91.3% to 95.8%) and 93.5% (90.9% to 95.5%) for seg-
mentsof1cmormoreand2cmormore,respectively.
The likelihood of being positive for trefoil factor 3 was
statistically associated with the length of the segment
affected by Barrett’s oesophagus (P=0.009 for circum-
ferential length and P=0.02 for maximal length;
table 2). Thirty false positives occurred, of which six
had some evidence of columnar lined epithelium (<1
cm) that did not fulfil the diagnostic criteria for this
study. Hence, for segments of 1 cm or more, trefoil
factor 3 yielded a sensitivity of 73.3% (44.9% to
Table 1 |Characteristics of participants. Values are numbers (percentages) unless stated
otherwise
Characteristics
All participants
(n=501)
Men
(n=229)
Women
(n=272)
Median (range) age (years) 62 (56 to 66) 62 (50 to 70) 62 (50 to 70)
Body mass index:
Missing data 2 (0.4) 0 (0) 2 (0.7)
Underweight 3 (0.6) 1 (0.4) 2 (0.7)
Normal 79 (15.8) 28 (12.2) 51 (18.8)
Pre-obese 187 (37.3) 97 (42.4) 90 (33.1)
Obese 230 (45.9) 103 (45.0) 127 (46.7)
Waist to hip ratio:
Missing data 5 (1.0) 2 (0.9) 3 (1.1)
Low risk 163 (32.5) 109 (47.9) 54 (19.9)
Medium risk 136 (27.1) 68 (29.7) 68 (25.0)
High risk 197 (39.3) 50 (21.8) 147 (54.0)
Ethnic origin:
White 480 (95.8) 215 (93.9) 265 (97.4)
Other 21 (4.2) 14 (6.1) 7 (2.6)
Education level:
No answer 12 (2.4) 6 (2.6) 6 (2.2)
School until age16 234 (46.7) 97 (44.4) 137 (50.4)
School until age 18 119 (23.8) 50 (21.8) 69 (25.4)
University degree 36 (7.2) 21 (9.2) 15 (5.5)
Postgraduate/professional qualification 100 (20.0) 55 (24.0) 45 (16.5)
Smoking status (pack years):
Never 217 (43.3) 86 (37.6) 131 (48.2)
<30 197 (39.3) 95 (41.5) 102 (37.5)
≥30 87 (17.4) 48 (21.0) 39 (14.3)
Alcohol consumption (units/week):
None 114 (22.8) 38 (16.6) 76 (27.9)
1-15 304 (60.7) 131 (57.2) 173 (63.6)
16-21 35 (7.0) 23 (10.0) 12 (4.4)
>21 48 (9.6) 37 (16.2) 11 (4.0)
Symptoms (GERD impact scores
13):
Very well controlled 35 (7.0) 20 (8.7) 15 (5.5)
Fairly controlled 99 (19.8) 43 (18.8) 56 (20.6)
Uncontrolled 136 (27.1) 77 (33.6) 59 (21.7)
Poorly controlled 195 (38.9) 77 (33.6) 118 (43.4)
Very poorly controlled 36 (7.2) 12 (5.2) 24 (8.8)
Current use of acid suppressants:
Antacids 67 (13.4) 29 (12.6) 38 (14.0)
Histamine receptor 2 antagonists 38 (7.6) 21 (9.2) 17 (6.2)
Proton pump inhibitors 286 (57.0) 122 (53.3) 164 (60.3)
Histamine receptor 2 antagonists+proton
pump inhibitors
9 (1.8) 6 (2.3) 3 (1.1)
None 101 (20.2) 51 (22.3) 50 (18.4)
GERD=gastro-oesophageal reflux disease.
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tive predictive value of 26.8% (14.2% to 42.9%), and a
negativepredictivevalueof 99.1%(97.8%to99.8%)in
thisparticularpopulationwithaprevalenceof3%.Pre-
sence of intestinal metaplasia at the cardia, hiatus her-
nia, or oesophagitis was not associated with the
likelihood of being positive for trefoil factor 3 (data
not shown).
Participant anxiety and test experience
Response rates were high for all questionnaires at all
time points: 496 (99%) at baseline, 466 (93%) at day 7,
and 415 (83%) at day 90. Anxiety levels were low in
most patients before and after the test. A subset (141/
496)ofpatients(28.4%,95%confidenceinterval24.4%
to31.6%)reportedhighanxietyscoresbeforeswallow-
ing the sponge that remained high during follow-up.
Themedianscoresforallparticipantswere 33.1(inter-
quartile range 26.6-43.3) at day 0, 30.0 (20.0-40.0) at
day 7, and 26.6 (20.0-36.6) at day 90 (fig 4). The scores
on the impact of event scale remained constant at days
7 and 90 after the Cytosponge test, with less than 4.5%
(95% confidence interval 2.8% to 6.1%) of participants
displaying significant distress for any subscore at any
time point (fig 4). The median (interquartile range)
scores for the visual analogue scale were 7.0 (5.0-8.0)
atthetimeofthetest,6.0(5.0-8.0)atday7,and6.0(4.0-
7.0) at day 90 (fig 4).
DISCUSSION
The Cytosponge test is a safe and well tolerated
method to screen for Barrett’s oesophagus that can be
carriedoutinaprimarycaresetting.Inthispopulation
with a history of reflux disease the prevalence of
Table 2 |Characteristics of patients with diagnosed Barrett’so e s o p h a g u s
Patient Sex Age
Body
mass
index
Waist to
hip ratio
Highest
educational
attainment
Smoking
(pack
years)
Alcohol
(units/
week)
Symptom
control Drugs
Barrett’s
oesophagus or
adenocarcino-
ma in first
degree relative
Circumfer-
ential
length (cm)
Maximal
length
(cm)
Cytosponge
test result
Practice A:
Patient 1 Male 69 27.5 1.00 School to 16 0 14 Poor Antacids No 1 3 Positive
Practice B:
Patient 1 Male 70 31.6 1.03 School to 16 0 10 Uncontrol-
led
Proton pump
inhibitors
No 4 6 Positive
Practice C:
Patient 1 Female 54 39.8 0.86 School to 16 0 2 Poor Antacids+proton
pump inhibitors
No 1 2 Positive
Patient 2 Female 58 27.8 0.89 School to 16 28 10 Poor Antacids+proton
pump inhibitors
No data 4 6 Positive
Patient 3 Female 67 35.1 0.79 School to 18 3 0 Fair Proton pump
inhibitors
Yes 2 2 Positive
Patient 4 Male 62 24.2 0.97 School to 18 52 2 Poor Proton pump
inhibitors
Yes 1 4 Negative
Practice D:
Patient 1 Male 52 29.0 0.96 School to 18 8 10 Very well Antacids No 6 6 Positive
Practice E:
Patient 1 Female 66 37.2 0.95 School to 16 37 0 Fair Antacids+proton
pump inhibitors
No 2 5 Negative
Practice F:
Patient 1 Male 61 31.7 1.02 School to 16 32 10 Uncontrol-
led
Antacids No 8 8 Positive
Practice G:
Patient 1 Male 66 32.4 1.10 School to 16 31 2 Poor Proton pump
inhibitors
No 5 7 Positive
Practice H:
Patient 1 Male 64 24.8 0.86 School to 18 0 6 Fair Proton pump
inhibitors
No 1 2 Negative
Patient 2 Male 64 28.4 0.99 University 28 1 Very well Proton pump
inhibitors
No 3 5 Positive
Patient 3 Male 59 23.4 0.92 School to 18 23 2 Fair Antacids
+histamine
receptor 2
antagonists
Yes 2 4 Positive
Practice I:
Patient 1 Female 63 33.5 0.85 School to 16 0 0 Poor Proton pump
inhibitors
No 9 9 Positive
Practice J:
Patient 1 Female 70 32.0 0.83 School to 16 0 4 Poor None No 1 2 Negative
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cm or more was 3.0%, for which trefoil factor 3 had a
sensitivity and specificity of 73.3% and 93.8%, respec-
tively. The sensitivity increased to 90.0% for segments
of 2 cm or more. This study was not, however,
designed to estimate test characteristics with high pre-
cision, and the estimate of sensitivity has wide confi-
dence limits. Further evaluation in a larger cohort is
now warranted.
Strengths and weaknesses of the study
The attendance rate of 504 (18.7%) is consistent with
the 16.3% reported in a previous endoscopic study in
theprimarycaresetting.
25Thisshouldbeconsideredin
the context of a study that involved two procedures,
including a hospital visit for gastroscopy. Recruitment
rates for this study should not be seen as surrogate for
uptake of this test if it were rolled out in a nationwide
screening programme, which would be accompanied
with major consumer awareness campaigns. This
response bias may have resulted in people with more
significant symptoms presenting or people with more
positive attitudes towards receiving a screening test.
Based on sex and age distribution, the non-responders
and responders originated from a homogeneous
population. Our preliminary data suggest that the test
wasacceptabletomostofthosewhoparticipatedinthe
study.Althoughwedidnotfindevidenceofsignificant
psychological distress associated with the screening
test in most of the participants, a subpopulation
seemed to have high levels of anxiety at baseline,
which persisted at day 90: this high level of anxiety
may therefore have little to do with the test.
Competing technologies currently undergoing eva-
luation include ultrathin transnasal endoscopy and
video capsule endoscopy, which remain expensive
and limited to specialist centres; furthermore, endo-
scopy using a video capsule does not permit cell sam-
pling, which remains a critical component for
diagnosis.
2627 The sensitivity and specificity for the
diagnosis of Barrett’s oesophagus, even for the video
capsule, remain relatively low, with values of 78% and
88%, respectively.
28
Comparison with other studies
The3.0%prevalenceofBarrett’soesophagusreported
here is in keeping with previous published studies. In
EuropeandtheUnitedStates,aprevalenceof2.3-2.6%
was reported for any length of Barrett’s oesophagus in
patients with reflux and 0.2-0.5% for segments greater
Table 3 |Comparison between patients with and without Barrett’s oesophagus stratified per circumferential length cut-off point of affected segment. Data are
medians (interquartile ranges) unless stated otherwise
Characteristics
Circumferential length ≥1 cm Circumferential length ≥2c m
Barrett’s oesophagus
(n=15)
No Barrett’s oesophagus
(n=486) P value
Barrett’s oesophagus
(n=10)
No Barrett’s oesophagus
(n=491) P value
Male to female ratio 1.5:1 0.84:1 0.26 1.75:1 0.84:1 0.36
Age 64.0 (59.0 to 67.0) 62.0 (56.0 to 66.0) 0.18 63.5 (58.7 to 66.2) 62.0 (56.0 to 66.0) 0.39
Body mass index 31.6 (27.5 to 33.5) 29.4 (26.2 to 32.9) 0.55 31.6 (27.8 to 33.5) 29.4 (26.2 to 32.9) 0.59
Waist to hip ratio 0.95 (0.86 to 0.99) 0.91 (0.85 to 0.96) 0.16 0.96 (0.89 to 1.02) 0.91 (0.85 to 0.96) 0.06
Smoking (pack years) 8.0 (0.0 to 31.4) 0.4 (0.0 to 19.5) 0.30 23.0 (3.0 to 31.0) 0.3 (0.0 to 19.2) 0.03
Alcohol consumption (units/week) 4.0 (2.0 to 10.0) 6.0 (1.0 to 14.0) 0.24 2.0 (0.0 to 10.0) 6.0 (1.0 to 14.0) 0.09
Symptoms (GERD score)
13 4.0 (2.0 to 6.0) 4.0 (2.0 to 6.5) 0.67 4.0 (2.0 to 6.0) 4.0 (1.7 to 6.1) 0.99
Acid suppressants* (%) 73.3 66.2 0.36 80.0 66.2 0.26
GERD=gastro-oesophageal reflux disease.
*Proton pump inhibitors or H2 receptor antagonists, or both.
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Fig 4 | Participants’ experience, anxiety, and distress related to Cytosponge test. Anxiety measured at day 0, 7, and 90 using six item short form short form
Spielberger state trait anxiety inventory (values >40 denote clinically significant anxiety). Distress associated with Cytosponge test measured using impact of
events scale. Intrusion and avoidance scores >19 denote high impact of test and >38 for total score. Participants rated their experience of Cytospongeu s i n ga
visual analogue scale, with 0 representing the “worst experience” and 10 the “best experience”
RESEARCH
page 6 of 8 BMJ | ONLINE FIRST | bmj.comthan 2 cm.
252930 The possibility that those who agreed
to take part had more severe symptoms of reflux may
explain the slightly higher prevalence reported here.
Much debate has been about the clinical significance
of “short segments” of Barrett’s oesophagus and the
presence of gastric versus intestinal metaplasia, and
while carrying out this study the diagnostic criteria
have continued to alter.
31 However, for both circum-
ferentiallengthcriteria(≥1cmand≥2cm),thesensitiv-
ity, specificity, and negative predictive value of our
Cytosponge test compared favourably with data from
screening tests using mammography for breast cancer
screening, prostate serum antigen testing for prostate
cancer, and faecal occult blood testing for colorectal
cancer.
32-34 Since screening detected cases will result
in endoscopic confirmation and surveillance, changes
to drugs, and treatment such as radiofrequency
ablation,
635we believethat the test shouldbe designed
todetectclinicallysignificantpatientswhowouldmost
likely benefit from surveillance or endoscopic treat-
ment.AscreeningtestforBarrett’soesophagusshould
have high specificity to avoid unnecessary confirma-
tory endoscopies or interventions. Barrett’s oesopha-
gus meets many of the established criteria for
population screening.
36
Implications for clinicians and policy makers
Barrett’soesophagusisanimportantpublichealthpro-
blemintheWest
7andthemetaplasia-dysplasia-adeno-
carcinomasequenceiswelldescribed.
37Thisstudyhas
shown the Cytospongetobe simple,safe, and accepta-
ble to the population considered to be at risk (patients
with reflux) and seems reasonably accurate. Further-
more, the binary scoring for trefoil factor 3 makes the
test amenable to automation. Further application of
risk models may be required to determine the optimal
target population (symptoms only, men or both sexes,
obese only).
38 In the current environment endoscopic
screeningforBarrett’soesophagusfollowedbysurveil-
lanceisnotdeemedtobecosteffective.
39However,the
Cytosponge might prove a more cost effective
approachtoscreeningasnohardwareneedstobepur-
chasedandonlyminimaltrainingisrequired,suchthat
the test could be carried out by a practice nurse in the
primarycare setting.Weare planninganin-depthcost
effectiveness analysis as part of a future screening
study. Furthermore, samples from the Cytosponge
have the potential to be adapted for surveillance, with
the application of suitable risk stratification
biomarkers.
4041
Conclusions
In summary, in this study we have shown that the
Cytosponge coupled with a single immunomarker is
a promising tool to screen for Barrett’s oesophagus in
the primary care setting and that further evaluation is
warranted. Our data are specific to a predominantly
white population in the United Kingdom. Generalisa-
tiontoothercommunitiesrequiresamulticentrestudy
and this would also provide more robust estimates of
diagnostic accuracy. The results presented here bring
screening for Barrett’s oesophagus into the realm of
possibility.
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